The Founder Effect? -FXIII Deficiency in Southeast Iran: A Molecular Study Report
Journal of Cellular & Molecular Anesthesia,
Vol. 5 No. 4 (2020),
AbstractBackground: Congenital factor XIII (FXIII) deficiency is an extremely rare bleeding disorder (RBD) with different clinical coagulation disorders and great impacts on the perioperative patient outcome. Its prevalence in Southeast Iran is approximately 4,000 times higher than the worldwide prevalence, with Trp187Arg (c.559T> C as the only causative mutation of FXIIID there. We investigated the founder effect of rs1742924, rs4960181, rs3778360 and rs4142290 using haplotype analysis to define the genetic phenomenon in this geographic region.
Materials and Methods: In a case-control study, 10 patients with FXIIID and 10 healthy individuals were assessed. Initially, Trp187Arg (c.559T> C) mutation was assessed in all study populations using a PCR-RFLP technique, then haplotype analysis was performed by assessing rs1742924, rs4960181, rs3778360 and rs4142290 polymorphisms. Data were analyzed using a two-proportion z-test.
Results: All patients were homozygote for Trp187Arg (c.559T>C), and this mutation was not observed in any form of homozygote or heterozygote in the control group. Polymorphisms in rs1742924, rs4960181, and rs377836 were homozygote (TT, GG, GG, respectively) and T, G, and G alleles distribution in cases and controls with significant difference (P<0.001, P<0.001, and P=0.01 respectively). Rs4142290 polymorphism showed no significant difference between patients and controls (P=0.3). Two types of haplotypes were observed in the case group, and haplotype number 1* was observed among 90% of them, while not observed in the control group.
Conclusion: It seems that founder effectors of haplotype number *1 have more antiquity versus other haplotypes, and probably founder effect is responsible for this high prevalence of FXIIID in the southeast of Iran.
- Key words: Factor XIII deficiency, Rare bleeding disorder, Founder effect
How to Cite
Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci. 2001;936:291-311.
Muszbek L, Bereczky Z, Bagoly Z, Komáromi I, Katona É. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91(3):931-72.
Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII Deficiency. Semin Thromb Hemost. 2009;35(4):426-38.
Anwar R, Gallivan L, Miloszewski KJ, Markham AF. Factor XIII deficiency causing mutation, Ser295Arg, in exon 7 of the factor XIIIA gene. Thromb Haemost. 2000;84(4):591-4.
Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev. 2016;30(6):461-75.
Jennings I, Kitchen S, Woods TA, Preston FE. Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study. J Thromb Haemost. 2003;1(12):2603-8.
Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek L. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost. 2011;9(7):1404-6.
Naderi M, Dorgalaleh A, Alizadeh S, Tabibian S, Hosseini S, Shamsizadeh M, et al. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency. Int J Hematol. 2014;100(5):443-9.
Dorgalaleh A, Kazemi A, Zaker F, Shamsizadeh M, Rashidpanah J, Mollaei M. Laboratory Diagnosis of Factor XIII Deficiency, Routine Coagulation Tests with Quantitative and Qualitative Methods. Clin Lab. 2016;62(4):491-8.
Naderi M, Dorgalaleh A, Alizadeh S, Tabibian S, Bamedi T, Karimi M. Molecular Analysis Of The Largest Group Of Patients With Factor XIII Deficiency In Southeast Of Iran. Blood. 2013;122(21):4780.
Dorgalaleh A, Tabibian S, Shams M, Majid G, Naderi M, Casini A, et al. A Unique Factor XIII Mutation in Southeastern Iran with an Unexpectedly High Prevalence: Khash Factor XIII. Semin Thromb Hemost. 2019;45(1):43-9.
Dorgalaleh A, Assadollahi V, Tabibian S, Shamsizadeh M. Molecular Basis of Congenital Factor XIII Deficiency in Iran. Clin Appl Thromb Hemost. 2018;24(2):210-6.
Trinh CH, Sh Elsayed W, Eshghi P, Miri-Moghaddam E, Zadeh-Vakili A, Markham AF, et al. Molecular analysis of sixteen unrelated factor XIIIA deficient families from south-east of Iran. Br J Haematol. 2008;140(5):581-4.
Eshghi P, Cohan N, Lak M, Naderi M, Peyvandi F, Menegatti M, et al. Arg77His and Trp187Arg are the most common mutations causing FXIII deficiency in Iran. Clin Appl Thromb Hemost. 2012;18(1):100-3.
Cromie GA, Leach DR. Control of crossing over. Mol Cell. 2000;6(4):815-26.
Ott J, Wang J, Leal SM. Genetic linkage analysis in the age of whole-genome sequencing. Nat Rev Genet. 2015;16(5):275-84.
Sprecher CJ, Puers C, Lins AM, Schumm JW. General approach to analysis of polymorphic short tandem repeat loci. Biotechniques. 1996;20(2):266-76.
Ferreira MA. Linkage analysis: principles and methods for the analysis of human quantitative traits. Twin Res. 2004;7(5):513-30.
Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol. 2016;95(3):451-5.
Tamaddon G, Kazemi A, Rastgarlari G, Ala F, Hejazi S. Molecular Basis of Inherited Factor XIII- A Deficiency among Patients from Sistan - Baluchestan . Zahedan J Res Med Sci 2010;11(4):e94357.
Pulst SM. Genetic linkage analysis. Arch Neurol. 1999;56(6):667-72.
Rahim NG, Harismendy O, Topol EJ, Frazer KA. Genetic determinants of phenotypic diversity in humans. Genome Biol. 2008;9(4):215.
Papachristou C, Lin S. Microsatellites versus Single-Nucleotide Polymorphisms in confidence interval estimation of disease loci. Genet Epidemiol. 2006;30(1):3-17.
Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost. 2013;39(6):621-31.
Wheeler AP, Gailani D. Why factor XI deficiency is a clinical concern. Expert review of hematology. 2016;9(7):629-37.
Naderi M, Alizadeh S, Tabibian S, Hosseini S, Varmaghani B, Shamsizadeh M, et al. Effect of Social Factors on the Highest Global Incidence of Congenital Factor XIII Deficiency in Southeast of Iran. Arch Iran Med. 2015;18(5):331.
Wheeler AP, Gailani D. Why factor XI deficiency is a clinical concern. Expert Rev Hematol. 2016;9(7):629-37.
Dorgalaleh A, Alavi SE, Tabibian S, Soori S, Moradi E, Bamedi T, et al. Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran. Hematology. 2017;22(4):224-30.
Mirakhorli M, Behboudi Farahbakhsh F, Reza Baghaipour M, Mahmoudi T, Jazebi M, Tabatabaei SM, et al. Factor XIII mutation spectrum in Iranian patients with hereditary factor XIII deficiency: Detection of 3 novel mutations. Int J Lab Hematol. 2019;41(3):e61-e5.
Payandeh M, Rahimi Z, Kansestani AN, Hemmati S, Aleyasin M, Zare ME, et al. Clinical features and types of von Willebrand disease in women with menorrhagia referred to hematology clinic of kermanshah. Int J Hematol Oncol Stem Cell Res. 2013;7(2):1-5.
Tavasoli B, Safa M, Dorgalaleh A, Ghasemi JB, Rezaei Makhouri F, Rezvani MR, et al. Molecular and clinical profile of congenital fibrinogen disorders in Iran, identification of two novel mutations. Int J Lab Hematol. 2020.
- Abstract Viewed: 114 times
- PDF Downloaded: 102 times